↓ Skip to main content

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Overview of attention for article published in Investigational New Drugs, October 2007
Altmetric Badge

Mentioned by

patent
2 patents

Citations

dimensions_citation
150 Dimensions

Readers on

mendeley
69 Mendeley
Title
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
Published in
Investigational New Drugs, October 2007
DOI 10.1007/s10637-007-9075-2
Pubmed ID
Authors

George R. Blumenschein, Merrill S. Kies, Vassiliki A. Papadimitrakopoulou, Charles Lu, Ashok J. Kumar, Justin L. Ricker, Judy H. Chiao, Cong Chen, Stanley R. Frankel

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
China 1 1%
France 1 1%
Unknown 66 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 22%
Student > Master 12 17%
Student > Bachelor 9 13%
Researcher 6 9%
Student > Doctoral Student 5 7%
Other 12 17%
Unknown 10 14%
Readers by discipline Count As %
Medicine and Dentistry 20 29%
Agricultural and Biological Sciences 12 17%
Biochemistry, Genetics and Molecular Biology 10 14%
Psychology 5 7%
Nursing and Health Professions 3 4%
Other 9 13%
Unknown 10 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2014.
All research outputs
#7,523,962
of 22,961,203 outputs
Outputs from Investigational New Drugs
#326
of 1,173 outputs
Outputs of similar age
#25,830
of 76,640 outputs
Outputs of similar age from Investigational New Drugs
#7
of 11 outputs
Altmetric has tracked 22,961,203 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,173 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,640 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.